Loading
A gene test on the tumour decides who can skip chemotherapy without losing protection.
This diagnostic-therapeutic pairing uses a gene-expression assay on the tumour, chiefly Oncotype DX and also MammaPrint, to decide which women with HR-positive, HER2-negative breast cancer can safely omit adjuvant cytotoxic chemotherapy. Proliferation- and oestrogen-receptor-related gene expression predicts both chemosensitivity and prognosis better than clinical and pathological factors alone. TAILORx in node-negative disease and RxPONDER in postmenopausal women with one to three involved nodes found no chemotherapy benefit at a recurrence score of 25 or below, and MINDACT with MammaPrint concurs; together these are three large prospective trials. Premenopausal women with intermediate scores still gain from chemotherapy, possibly through ovarian suppression.
Shares RxPONDER (SWOG S1007), TAILORx, Oncotype DX, HR-positive / HER2-negative breast cancer.
Shares MammaPrint (70-gene signature), RxPONDER (SWOG S1007), Oncotype DX, HR-positive / HER2-negative breast cancer.
Shares TAILORx, Oncotype DX, HR-positive / HER2-negative breast cancer.
Shares RxPONDER (SWOG S1007), Oncotype DX, HR-positive / HER2-negative breast cancer.
Shares RxPONDER (SWOG S1007), TAILORx, Oncotype DX.
Shares MammaPrint (70-gene signature), HR-positive / HER2-negative breast cancer.
Shares MammaPrint (70-gene signature), Oncotype DX, HR-positive / HER2-negative breast cancer.
Shares MammaPrint (70-gene signature), HR-positive / HER2-negative breast cancer.